LEXICON PHARMACEUTICALS INC | 1,265 Euro | -0,018 -1,40 % | |
| WKN: 936717 ISIN: US5288721047 Ticker-Symbol: LX3 | Frankfurt | 10.02.12 | 08:18 Uhr |
Branche BiotechnologieAktienmarkt NASDAQ Biotech |
|
| Zeit | Aktuelle Nachrichten | Leser | Medien | |
|---|---|---|---|---|
| 08.02. | 2-Star Stocks Poised to Plunge: Lexicon Pharmaceuticals? | 1 | Motley Fool | |
| 08.02. | Lexicon Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference | 31 | PR Newswire | |
| THE WOODLANDS, Texas, Feb. 7, 2012 /PRNewswire/ --Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will... Mehr lesen zu: Lexicon Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference | ||||
| 17.01. | Stock to Watch: Lexicon Pharmaceuticals Up 7.5% | 4 | SmarTrend | |
| 10.01. | Lexicon Pharmaceuticals has the Highest Enterprise Value to Sales Ratio in the Biotechnology Industry | 2 | SmarTrend | |
| 05.01. | Lexicon Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference | 35 | PR Newswire | |
| THE WOODLANDS, Texas, Jan. 4, 2012 /PRNewswire/ --Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Dr. Arthur T. Sands, president and chief executive officer, will present... Mehr lesen zu: Lexicon Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference | ||||
| 22.11. | Lexicon Pharma (LXRX) Commences 144.25M Common Rights Offering | 5 | StreetInsider.com | |
| 17.11. | CAPITAL ADJUSTMENT INFORMATION - 17.11.2011 - 2 | 104 | Xetra Newsboard | |
| FOLGENDE WERTPAPIERE WERDEN AM 17.11.2011 EX KAPITALMASSNAHME GEHANDELT. THE FOLLOWING SHARES ARE TRADED EX CAPITAL ADJUSTMENT ON 17.11.2011. INSTR ISIN INSTRUMENT NAME 5SS AU000000SXG4 SOUTHERN CROSS... Mehr lesen zu: CAPITAL ADJUSTMENT INFORMATION - 17.11.2011 - 2 | ||||
| 01.11. | LEXICON PHARMACEUTICALS, INC./DE - 10-Q, Quarterly Report | 5 | SEC Filings | |
| 01.11. | Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results | 16 | PR Newswire | |
| THE WOODLANDS, Texas, Nov. 1, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human... Mehr lesen zu: Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results | ||||
| 07.10. | Analyst View, Impact of Global Events - Research Report on Metabolix, Inc. and Lexicon Pharmaceuticals, Inc. | 12 | MarketWire | |
| HONG KONG -- (Marketwire) -- 10/07/11 -- Today, www.WorldStreetFundamentals.com released its industry report highlighting Metabolix, Inc. (NASDAQ: MBLX) and Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX).... Mehr lesen zu: Analyst View, Impact of Global Events - Research Report on Metabolix, Inc. and Lexicon Pharmaceuticals, Inc. | ||||
| 06.09. | Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference | 23 | PR Newswire | |
| THE WOODLANDS, Texas, Sept. 6, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced... Mehr lesen zu: Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference | ||||
| 30.08. | Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference | 27 | PR Newswire | |
| THE WOODLANDS, Texas, Aug. 30, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced... Mehr lesen zu: Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference | ||||
Startseite • Nachrichten • Aktienkurse • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Chartanalysen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage
